Interim treatment selection in drug development

Statistics in Biosciences

Volumn 1, Issue 2, 2009, Pages 268-288

  Li, Gang ^a   Wang, Yining ^a   Ouyang, S Peter ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

Clinical trial; Closure principle; Family wise error rate; Interim treatment selection; Multiple comparison; Step down approach

Indexed keywords

EID: 84867122721     PISSN: 18671764     EISSN: 18671772     Source Type: Journal    
DOI: 10.1007/s12561-009-9017-y     Document Type: Article

References (8)

1. FDA (2008) Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention
2. Friede T, Stallard N (2008) A comparison of methods for adaptive treatment selection. Biom J 50:767-781
3. Kelly PJ, Stallard N, Todd S (2005) An adaptive group-sequential design for Phase II/III clinical trials that select a single treatment from several. J Biopharm Stat 15:641-658
4. Koenig F, Brannath W, Bretz F, Posch M (2008) Adaptive Dunnett tests for treatment selection. Stat Med 27:1612-1625
5. Lan KKG, Soo Y, Shun Z (2005) Normal approximation for two-stage winner design. In: Hsiung AC, Ying Z, Zhang CH (eds) Random walks, sequential analysis and related topics. World Scientific, Singapore, pp 28-43
6. Li G, Zhu Z, Ouyang SP, Xie J, Deng L, Law G (2009) Adaptive designs for interim dose selection. Stat Pharm Res 1:366-376
7. Liu Q, Peldger GW (2005) Phase 2 and 3 combination designs to accelerate drug development. J Am Stat Assoc 100:493-536
8. Marcus R, Peritz E, Gabriel KR (1976) On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660